Zosano Pharma Corp. (ZSAN) Stock Trends Lower Ahead of Type C Meeting with U.S FDA
Zosano Pharma Corp. (ZSAN) stock prices were down by 3.98% some time after market trading commenced on October 4th, 2021. This brought the price per share down to USD$0.68 early on in the trading day. ZSAN Stock’s Type C Meeting October 4th, 2021 saw ZSAN stock announce having been granted a Type C written response […]
CTI BioPharma Corp. (CTIC) Stock Trends Lower Following Failure of PRE-VENT Trial to Meet Primary Endpoint
CTI BioPharma Corp. (CTIC) stock prices were down by 3.32% shortly after market trading commenced on October 4th, 2021. This brought the price per share down to USD$2.76 early on in the trading day. CTIC Stock’s PRE-VENT Trial October 1st 2021 saw CTIC stock announced topline results from its PRE-VENT clinical trial of pacritinib. The […]
Inhibikase Therapeutics, Inc. (IKT) stock is rising today: Here’s Why
Shares of the Inhibikase Therapeutics, Inc. (IKT) stock were rising in the intraday session following the release of interim three-month results of IKT-148009. IKT stock price saw a push of $1.57% to reach $1.97 a share at the time of this writing. The trading volume as of now was 575,240, higher than the average trading […]
Selecta Biosciences Inc. (SELB) Stock Trends Higher Following Strategic Licensing Agreement with Takeda
Selecta Biosciences Inc. (SELB) stock prices were up by 3.65% as of the market closing on October 1st, 2021. This brought the price per share up to USD$4.33 at the end of the trading day. SELB Stock Partners with Takeda October 4th 2021 saw SELB stock announce having entered into a strategic licensing agreement. The […]
Why has Xenon Pharmaceuticals Inc. (XENE) stock skyrocketed today?
Xenon Pharmaceuticals Inc. (XENE) stock skyrocketed today after the announcement of Positive Topline results of XEN1101. XENE stock price saw a surge of 89.10% to reach $29.50 a share at the time of this writing. The stock was bullish in the previous trade and went up by 2.09% at closing. Xenon Pharmaceutical is the clinical-stage […]
Naked Brand Group Limited (NAKD) shows a decline, what’s going on?
Naked Brand Group Limited (NAKD) saw a decrease of 3.33% and stands at $0.65 in the premarket today. However, the last trading session closed at $0.675 with a decline of 4.96%. Update to Chairman’s Address From 2021 Annual Meeting of Shareholders On 24th September 2021, Chairman and Chief Executive Officer Justin Davis-Rice provided an update […]
Why did Sonnet Biotherapeutics Holdings Inc (SONN) stock rally today?
Sonnet Biotherapeutics Holdings Inc (SONN) stock rallied in the Pre-Market today on October 4, 2021. SONN stock price saw a push of 7.69% to reach $0.70 a share at the time of this writing. The stock was also green in the previous trade and went up by 7.1% bringing per share price $0.649 at closing. […]
OpGen Inc. (OPGN) Stock Surges with News of Commencement of Clinical Trial for Unyvero
OpGen Inc. (OPGN) stock prices were down by 4.17% as of the market closing on October 1st, 2021. This brought the price per share down to USD$2.76 at the end of the trading day. Subsequent premarket fluctuations have seen the stock surge by 17.39%, bringing it up to USD$3.24. OPGN Stock Starts Clinical Trials September […]
ENGlobal Corporation (ENG) Stock jumped 5.35% In premarket Trading. Here’s Why?
ENGlobal Corporation (ENG) experienced an incline of 5.35% in the premarket. However, the last trading session closed at $3.18 with an incline of 19.1%. Annual Meeting Results ENG announced the annual meeting results on 27th August 2021. According to the report, the meeting was attended by about 58 percent of ENGlobal’s total outstanding common shares. […]
Farmmi, Inc. (FAMI) Stock Is Rising in Premarket Today – What’s causing it to rise?
Farmmi, Inc. (FAMI) has surged 12.44% in the premarket today after the company issues a CEO update letter. However, the last trading session closed at $0.3536 with a decrease of 23.55%. CEO Update Letter FAMI issued a CEO update letter on 3rd October 2021. The company sent a CEO update letter outlining an acquisition that […]
